Sp475
AGA LIVING GUIDELINES: MANAGEMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS Q&A
Date
May 19, 2024
Explore related products in the following collection:
Presenters
Mayo Foundation for Medical Education and Research
University of California Los Angeles
Tracks
Related Products
A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY REVEALS THE COMBINATION OF RNA ANALYSIS WITH DNA-BASED NEXT-GENERATION SEQUENCING (NGS) IMPROVES THE PREOPERATIVE CLASSIFICATION OF PANCREATIC CYSTS AND IDENTIFICATION OF ADVANCED NEOPLASIA
BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…
RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND STUDY
BACKGROUND: Risankizumab (RZB), a monoclonal antibody targeting interleukin-23 p19, was evaluated for maintenance therapy in patients with moderately to severely active ulcerative colitis (UC) and clinical response to RZB intravenous (IV) induction treatment in a phase 3 double-blind, placebo (PBO)…
Tadataka “Tachi†Yamada, MD, Lecture: Food as Medicine: How to Utilize Diet and Enhance Nutrition to Improve Outcomes in Foregut Diseases
LIVE STREAM SESSION This session will review evidence-based dietary approaches to management of patients with common foregut diseases including gastroesophageal reflux disease, eosinophilic esophagitis, and motility disorders of the esophagus and stomach…
